Management Statement

3 Months Ended

Mar. 31, 2013

Management Statement

1. Management Statement

In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2013, and the results of operations and cash flows for the three-month periods ended March 31, 2013 and 2012.

In December 2012, the Company obtained accelerated approval from the U.S. Food and Drug Administration (“FDA”) to sell its first new cancer medicine, Iclusig^® (ponatinib), and commenced sales and marketing of Iclusig in the United States in January 2013. Accordingly, the Company’s financial statements as of and for the three-month period ended March 31, 2013 include transactions related to commercialization that did not exist in prior periods. The results of operations for the three-month period ended March 31, 2013 are not necessarily indicative of the results to be expected for any other period or the full year. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, which includes consolidated financial statements and notes thereto for the years ended December 31, 2012, 2011 and 2010.